Hydrogen peroxide mediated formation of heteroaryl ethers from pyridotriazol-1-yloxy heterocycles and arylboronic acids
Pyridotriazol-1-yloxypyrimidine 3 reacts with arylboronic acids under palladium-free, Cs2CO3, (0.8%) H2O2, and DME conditions to produce heteroaryl ethers 4-16 in good yields comparable to the oxidative palladiu
Bardhan, Sujata,Tabei, Keiko,Wan, Zhao-Kui,Mansour, Tarek S.
supporting information; experimental part
p. 5733 - 5736
(2009/12/06)
Heteroaryl ethers by oxidative palladium catalysis of pyridotriazol-1-yloxy pyrimidines with arylboronic acids
The oxidative palladium-catalyzed cross-coupling of pyrimidines containing pyridotriazol-1-yloxy (OPt) as either a urea or an amide functional group with arylboronic acids in the presence of Cs2CO3 in DME containing 0.6-1.0% H2
Bardhan, Sujata,Wacharasindhu, Sumrit,Wan, Zhao-Kui,Mansour, Tarek S.
supporting information; experimental part
p. 2511 - 2514
(2009/10/18)
HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION
The present invention relates to processes for the preparation of heteroaryl ethers. In some embodiments, the processes relate to cross coupling reactions between triazol-1-yloxy and triazol-1-yl heterocycles with aryl boronic acids. In a further aspect, this invention also relates to compounds that are useful for the treatment of oncological diseases or disorders, and for the treatment of inflammation.
-
Page/Page column 34
(2009/12/05)
CHEMOKINE RECEPTOR BINDING COMPOUNDS
The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
-
Page/Page column 65
(2010/11/26)
More Articles about upstream products of 926304-76-9